GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Shiller PE Ratio

SILO Pharma (SILO Pharma) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


SILO Pharma Shiller PE Ratio Historical Data

The historical data trend for SILO Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma Shiller PE Ratio Chart

SILO Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SILO Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SILO Pharma's Shiller PE Ratio

For the Biotechnology subindustry, SILO Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Shiller PE Ratio falls into.



SILO Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

SILO Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, SILO Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.28/131.7762*131.7762
=-0.280

Current CPI (Mar. 2024) = 131.7762.

SILO Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.444 100.560 -0.582
201409 -0.331 100.428 -0.434
201412 -0.135 99.070 -0.180
201503 0.028 99.621 0.037
201506 0.016 100.684 0.021
201509 -0.456 100.392 -0.599
201512 0.000 99.792 0.000
201603 -0.103 100.470 -0.135
201606 -0.434 101.688 -0.562
201609 -0.431 101.861 -0.558
201612 -0.143 101.863 -0.185
201703 0.500 102.862 0.641
201706 -0.076 103.349 -0.097
201709 -0.518 104.136 -0.655
201712 0.207 104.011 0.262
201803 0.017 105.290 0.021
201806 -0.500 106.317 -0.620
201809 -0.198 106.507 -0.245
201812 -0.500 105.998 -0.622
201903 -0.500 107.251 -0.614
201906 -0.500 108.070 -0.610
201909 -0.500 108.329 -0.608
201912 -0.500 108.420 -0.608
202003 -0.500 108.902 -0.605
202006 -2.000 108.767 -2.423
202009 -0.500 109.815 -0.600
202012 -0.500 109.897 -0.600
202103 -1.500 111.754 -1.769
202106 -0.238 114.631 -0.274
202109 3.160 115.734 3.598
202112 -0.380 117.630 -0.426
202203 -0.310 121.301 -0.337
202206 -0.330 125.017 -0.348
202209 -0.490 125.227 -0.516
202212 -0.580 125.222 -0.610
202303 -0.290 127.348 -0.300
202306 -0.320 128.729 -0.328
202309 -0.210 129.860 -0.213
202312 -0.380 129.419 -0.387
202403 -0.280 131.776 -0.280

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SILO Pharma  (NAS:SILO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


SILO Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma (SILO Pharma) Business Description

Traded in Other Exchanges
N/A
Address
560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632
SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797

SILO Pharma (SILO Pharma) Headlines